Can peritumoral edema evaluated by Magnetic Resonance Imaging before neoadjuvant chemotherapy predict complete pathological response in breast cancer?

Autor: Cakir Pekoz B; Department of Radiology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey., Dilek O; Department of Radiology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey., Koseci T; Department of Medical Oncology and Internal Medicine, Cukurova University Faculty of Medicine, Adana, Turkey., Tas ZA; Department of Pathology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey., Irkorucu O; Department of Clinical Sciences, University of Sharjah, College of Medicine, Sharjah, United Arab Emirates., Gulek B; Department of Radiology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
Jazyk: angličtina
Zdroj: Scottish medical journal [Scott Med J] 2023 Aug; Vol. 68 (3), pp. 121-128. Date of Electronic Publication: 2023 May 09.
DOI: 10.1177/00369330231174230
Abstrakt: Background and Aims: The complete pathological response (pCR) following neoadjuvant chemotherapy (NAC) in breast cancer is essential for the accurate prediction of prognosis. We aimed to evaluate the efficacy of the presence and type of peritumoral edema detected by magnetic resonance imaging (MRI) in predicting pCR to NAC in breast cancer patients.
Methods and Results: One hundred five patients with the diagnosis of invasive carcinoma were evaluated by MRI before NAC. Edema was evaluated in fat-suppressed T2-weighted images. The patients were categorized into three groups: patients with no peritumoral edema, patients with peritumoral edema, and patients demonstrating subcutaneous edema. The cases were categorized as being pCR and non-pCR. Molecular subtypes, lymphovascular invasion (LVI), tumor size, and apparent diffusion coefficient (ADC) were evaluated. A positive relationship was found between the presence of edema and tumor size. Subcutaneous edema was found to be statistically higher in non-pCR patients. While the number of pCR patients with subcutaneous edema was 17 (30.4%), the number of non-pCR patients with subcutaneous edema was 26 (53.1%) ( p   =  0.018). LVI was found to be statistically higher in patients with edema. The number of edema-negative and LVI (+) patients was 4 (15.4%), while the number of edema-positive and LVI (+) patients was 28 (35.4%) ( p  = 0.042). Intratumoral and peritumoral ADC values were significantly higher in tumors with edema.
Conclusion: The presence of subcutaneous edema and LVI may be utilized for the prediction of pCR outcomes in breast cancer patients scheduled for NAC treatment.
Databáze: MEDLINE